Cancer Chemotherapy and Pharmacology

, Volume 27, Issue 2, pp 161–163 | Cite as

VIM-D salvage chemotherapy in Hodgkin's disease

  • Julia K. Phillips
  • Ruth L. Spearing
  • John M. Davies
  • Charles R. M. Hay
  • Huw Parry
  • John R. Nash
Original Articles Salvage Chemotherapy, Hodgkin's Disease

Summary

A total of 15 patients with relapsed or resistant Hodgkin's disease were treated with a combination of etoposide (VP16), ifosfamide, mitozantrone and dexamethasone (VIM-D). The regime was well tolerated, the only major toxicity being myelosuppression. Complete remissions (CRs) were obtained in 4 patients and were maintained for 2,4, 10 and 14 months, 10 subjects subsequently received an autologous bone marrow transplant with highdose chemotherapy (ABMT). Previous exposure to VIMD did not appear to predict for or prejudice the response to subsequent ABMT.

References

  1. 1.
    Bonnadonna G, Santoro A (1982) Drug selection in the treatment of Hodgkin's disease. Haematol Oncol 1: 3–12Google Scholar
  2. 2.
    Coltman CA, Mc Daniel TM, Balcerzak SP, Morrison FS, von Hott DD (1983) Mitozantrone hydrochloride (NSC-310739) in lymphoma. Invest New Drugs 1: 65–70Google Scholar
  3. 3.
    Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, haurani F, Blom J, Spurr CL Glidewell OJ, Gottlieb AJ, Holland JF (1980) A new effective four drug combination of CCNU [1(2chlorethy)-3-cyclohexyl-1-nitrosea] (NSC-79038), vinblastine, prednisone and procarbazine for the treatment of advanced Hodgkin's disease. Cancer 46i: 654–662Google Scholar
  4. 4.
    Dady PJ, McElwain TJ, Austin DE, Barrett A, Peckham MJ (1982) Five years experience with ChlVPP: effective low toxicity combination chemotherapy for Hodgkin's disease. Br J Cancer 45: 851–859Google Scholar
  5. 5.
    Jagannath S, Dicke KA, Armitage JD, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G (1986) High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 104: 163–168Google Scholar
  6. 6.
    Klimo P, Connors JM (1985) MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3: 1174–1182Google Scholar
  7. 7.
    Santoro A, Viviani S, Bonfante V, Valagussa P, Bonnadonna G (1987) Results with salvage CEP in Hodgkin's disease (HD) resistant to MOPP and ABVD. Proceedings, ECCO-4. vol 272. Artes Graf Danubio, Madrid, p 1040Google Scholar
  8. 8.
    Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1989) A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7: 1333–1340Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Julia K. Phillips
    • 1
  • Ruth L. Spearing
    • 1
  • John M. Davies
    • 1
  • Charles R. M. Hay
    • 1
  • Huw Parry
    • 2
  • John R. Nash
    • 3
  1. 1.Department of HaematologyRoyal Liverpool HospitalLiverpoolEngland
  2. 2.Department of HeamatologyYsbyty Gwynedd, PenrhosgarneddBangorWales, UK
  3. 3.Department of HistopathologyRoyal Liverpool HospitalLiverpoolEngland, UK

Personalised recommendations